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(SDS) with linezolid. The aim of the study was to estimate the budget impact of 
SDS vs conventional strategy (CS, only intravenous) with linezolid in Mexico, from 
the perspective of Instituto Mexicano del Seguro Social (IMSS). Methods: Budget 
impact analysis (BIA) considered direct medical costs of linezolid (intravenous 
and tablets), length of stay, physician visits, route of administration, laboratory 
and imaging tests, as well as outpatient control (unit costs extracted from IMSS 
sources). Costs are expressed in 2013 US$ (1US$:€ 0.719). The resource use profile 
was estimated by Delphi method in a panel of 10 experienced infectologists. A 
BIA considering two scenarios was performed: i) budget impact of use CS in 100% 
of cases of nosocomial pneumonia caused by GPB (15,135) and ii) budget impact 
of use of SDS only in candidates (7,718 cases), based on the National budget allo-
cated to health in 2013. Results: The per-patient average treatment cost (ATC) 
of SDS was $10,116 ($9,345-10,887) whereas the per-patient ATC of CS was $17,251 
($16,379-18,124). The scenario i) represents 2.79% of National budget allocated to 
health, whereas scenario ii) represents 2.19%. This means potential savings of 0.6% 
of National budget allocated to health ($55,078,697). With these resources, CS treat-
ment could be provided to 3,192 additional nosocomial pneumonia patients caused 
by GPB in Mexico. ConClusions: In the Mexican setting, SDS with linezolid in 
suitable patients is an intervention that could promote significant savings regarding 
the use of only intravenous form of the drug, which represents an opportunity to 
allocate scarce resources in a more efficient way.
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Potential of omega-3 fatty acid in PaRenteRal nutRition in 
geRmany: a Budget imPact analySiS
Pradelli L., Povero M.
AdRes HE&OR, Turin, Italy
objeCtives: The costs to the German hospitals of intensive care (ICU) patients 
and of surgical patients not admitted to the ICU were estimated in a previous cost-
effectiveness analysis of omega-3 FA-supplemented compared to standard PN regi-
mens. The supplementation with Omega-3 FA results in shorter LOS and reduced 
infection rate, with cost savings for 3,277 € per ICU patient and 1,515 € per not-ICU 
patients. We aimed to estimate the economic consequences of increasing the rate 
of omega-3 fatty acids (FA) supplemented parenteral nutrition (PN) regimens in 
German hospitals Methods: IMS-data recorded about 3 million lipid-containing 
PN days for Germany; the total number of patients in ICU or in ward receiving PN 
with lipids was estimated on average PN duration from the cost-effectiveness analy-
sis The costs related to the current use of omega-3 FA (about 29% of total lipid PN 
days) were compared with those expected with increasing percentages of omega-3 
FA-containing PN rates. Results: The yearly cost of the patient population (104,022 
ICU patients and 427,986 not-ICU patients) treated with current PN regimens mix 
amounts to about 6 billion Euro. The increase of omega-3 FA-containing PN propor-
tion up to 50% results in a saving of about 210 million Euro (2.7%); the exclusive 
use of omega-3 FA-containing PN regimes results in savings of 704 million Euro 
(11.6%). Encouraging omega-3 FA supplemented PN regimens is expected to save 
costs, because the use is associated with a reduction in hospital LOS (~ 850,000 days 
saved in the best scenario) and the number of nosocomial infections (~ 40,000 infec-
tions avoided in the best scenario). ConClusions: The potential of PN including 
omega-3 FAs in contributing to an improved quality of care/patient recovery and 
significant cost savings is not fully exploited in German hospitals.
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objeCtives: A new dry-powder inhaler combination for the treatment of asthma 
has appeared. The objective of the present study is to analyze the cost impact of the 
introduction of the new dry-powder inhaler (DPI) –beclomethasone dipropionate with 
formoterol combination (BEC/FOR) - in the treatment of the moderate to severe persis-
tent asthma Methods: A mathematical model was designed to estimate the finan-
cial impact of the partial substitution of DPI budesonide with formoterol (BUD/FOR) 
and DPI fluticasone propionate with salmeterol (FLU/SAL). Only direct health care 
costs were considered because the perspective of Spanish National Health Service 
(NHS) was adopted. The time horizon was four years Results: The prevalence is 
4.6% and it increases 0.26% yearly. Current annual total cost of treatment with BUD/
FOR and FLU/SAL is estimated in around 512; 538; 565 and 591 million € for 2013-2017 
respectively. The new total cost is estimated in about 511; 537; 562 and 587 million € 
with the introduction of BEC/FOR. The major determinants of costs were the exac-
erbations of asthma (44.5% of total cost), and the antiasthmatic drugs (40.2%). The 
pharmacological cost of BEC/FOR represented the 37.02% of the total of this option 
while those of FLU/SAL and BUD/FOR were the 39.75% and 41.27%, respectively. Finally, 
the introduction of BEC/FOR (share of 2; 4; 9 and 14% for 2013-2017) was associated 
with a roughly saving of 0.7; 1.2; 2.8 and 4.5 million € in the same time ConClusions: 
The utilization of beclomethasone dipropionate and formoterol in substitution of 
fluticasone and salmeterol, and budesonide and salmeterol, all of them as dry-powder 
inhaled, results in important savings of costs for the NHS
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objeCtives: The lack of treatment adherence and persistence is associated with 
poor clinical outcomes and higher costs. The aim of this study is to estimate 
the variation on COPD costs that may take place as a consequence of improving 
spite of high heterogeneity found in NI reports (which may decrease the quality of 
the information recorded), the local data reported in this study can help clinicians in 
the choice of first line antibiotics in order diminish the probability of unsuccessful 
treatment and additionally to reduce the emergence of resistant organisms, which 
could cause negative economic impact in the health care institutions.
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objeCtives: Palivizumab prophylaxis against respiratory syncytial virus (RSV) 
is provided monthly during the RSV season. CARESS is a prospective registry of 
infants who received ≥ 1 dose of palivizumab across 32 Canadian sites during 7 
seasons. The objective is to determine factors associated with palivizumab com-
pliance. Methods: Neonatal and demographic data were collected at enrolment. 
Palivizumab utilization, compliance, and outcomes related to respiratory illness 
(RI) and RSV hospitalization were collected monthly. Compliance was defined 
as receipt of all expected injections at 25–35 day intervals during the RSV sea-
son. Results: A total of 13,310 infants were enrolled. Infants received 89.0% ± 
18.23% of their expected injections and 9745 (73.2%) were administered within 
appropriate inter-dose intervals.Compliant versus non-compliant infants had a 
rate of 9.2 RSV and 57.5 RI versus 11.7 RSV and 65.5 RI hospitalizations / 100-patient-
years respectively. Compliance differed between prophylaxis indications (χ 2= 24.6, 
p< 0.0005); with congenital heart disease the most non-compliant (CHD; n= 668, 
47.2%), followed by chronic lung disease (CLD; n= 470, 44.8%), prematurity (≤ 35 
weeks gestational age; n= 3643, 41.6%) and other medical disorders (n= 831, 39.6%). 
A greater proportion of non-compliant infants were Aboriginal (4.8% vs. 2.4%, 
χ 2= 57.8, p< 0.0005), attended daycare (4.0% vs. 3.3%, χ 2= 5.0, p= 0.03), had a mother 
who smoked (17.1% vs. 12.0%, χ 2= 69.0, p< 0.0005), and lived with ≥ 1 smoker (31.7% 
vs.26.1%, χ 2= 49.7, p< 0.0005). Significant factors independently associated with com-
pliance (OR, 95%CI) were: maternal education (1.38, 1.22–1.58), Aboriginal descent 
(0.57, 0.47–0.70), smoke exposure (0.70, 0.52–0.94), CLD (0.74, 0.56–0.99), maternal 
smoking (0.79, 0.68–1.01), daycare (0.82, 0.68–0.99), and indication for prophylaxis. 
Compliance by both expected number of injections and inter-dose intervals was 
associated with lower hazard rates of RI hospitalization (HR= 0.86, 95%CI= 0.74-0.99, 
p= 0.04). ConClusions: Higher maternal education and lower RI hospitalization 
was associated with full compliance where as non-compliance was associated with 
other demographic factors and differed by palivizumab indication.
ReSPiRatoRy-Related diSoRdeRS – cost Studies
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objeCtives: The economic burden of asthma on the UK National Health Service 
(NHS) is the largest amongst allergic diseases, costing approximately £800 million 
per year. Current Global Initiative for Asthma guidelines recommend adding a long 
acting β 2-agonist (LABA) to a low-dose inhaled corticosteroid (ICS) in patients who 
are on ICS monotherapy and have uncontrolled asthma. The fixed-dose combina-
tion of fluticasone propionate and salmeterol (FLUT/SAL), available in a pressurized 
metered dose inhaler (pMDI) device, is the most commonly prescribed ICS/LABA 
combination. A new fixed-dose combination of fluticasone propionate and formo-
terol fumarate (FLUT/FORM) in pMDI is now available. In a 12 week non-inferiority 
study, FLUT/FORM demonstrated comparable efficacy to FLUT/SAL. This study esti-
mates the budget impact of using FLUT/FORM as an alternative to FLUT/SAL for 
an average NHS clinical commissioning group (CCG) within England. Methods: 
Current pMDI prescribing data were taken from a real-world UK patient database 
(Cegedim Strategic Data). Annual costs to the NHS for drug acquisition, administra-
tion, and monitoring were estimated for FLUT/FORM and FLUT/SAL. Annual cost 
data were used to estimate the potential budget impact for the use of FLUT/FORM 
versus FLUT/SAL, based on an estimated average population size for a CCG (260,000 
persons or 0.41% of the UK population). Results: Assuming similar levels of ICS 
use with both combination regimens, annual drug acquisition costs per person were 
lower with FLUT/FORM (£411.58) than with FLUT/SAL (£509.06). The difference in 
acquisition costs and otherwise comparable input costs between the treatments, 
results in potential annual savings of £61,952.14 for an average CCG, assuming 
uptake of FLUT/FORM over FLUT/SAL in 50% of existing patients. ConClusions: 
The comparable efficacy and lower acquisition costs for FLUT/FORM compared 
to FLUT/SAL make it a cost-saving option, from a NHS England CCG perspective, 
for the treatment of asthma patients requiring combination maintenance therapy 
using a pMDI.
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Muciño-Ortega E.2
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objeCtives: Previous reports of national literature estimated 15,135 cases of noso-
comial pneumonia caused by Gram-positive bacteria (GPB) in Mexico, of which 
approximately 51% (95%CI 43%-59%) are candidates to use the step-down strategy 
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COPD patients yields significant costs savings and has a beneficial effect on 
evaluated quality of life.
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objeCtives: To estimate health care costs for asthma patients with and without 
a COPD diagnosis. Methods: Asthma patients with and without diagnosed COPD 
were selected from the HealthCore Integrated Research Database covering admin-
istrative claims from approximately 27.6 million people in the USA. The index 
event was a patient’s first exacerbation defined as oral corticosteroid prescription 
fills or emergency department visits or inpatient visits with a primary diagnosis 
of asthma. Eligibility criteria were ≥ 1 asthma diagnosis, ≥ 1 exacerbation and 12 
months of continuous health plan enrolment on each side of the index date. Total 
all-cause and asthma-related direct health care costs for 12 months before and 
after the index date were calculated for all patients and those with and without a 
COPD diagnosis. Results: A total of 94,883 patients met all eligibility criteria, of 
these 15,127 (15.9%) had both asthma and COPD diagnoses. The mean patient age 
was 41.6 years and 62.4% were female. Co-morbid conditions were more common 
among asthma patients with a COPD diagnosis. Asthma-related direct costs repre-
sented 25-30% of all-cause direct health care costs for all patients. Among asthma 
patients, COPD and its associated co-morbidities roughly doubled all-cause and 
asthma related direct health care costs: mean annual pre-index all-cause health 
care costs were $20,012 (COPD diagnosis) versus $8,938 (no COPD diagnosis); mean 
annual pre-index asthma related costs were $5,623 (COPD diagnosis) versus $2,600 
(no COPD diagnosis). Mean annual post-index costs were almost unchanged: all-
cause costs of $21,692 (COPD diagnosis) versus $10,787 (no COPD diagnosis) and 
asthma-related costs of $5,242 (COPD diagnosis) versus $3,016 (no COPD diag-
nosis). ConClusions: The economic burden of asthma among patients with a 
COPD diagnosis in a US claims database is twice as high as those without a COPD 
diagnosis. Further research could adjust for the effects of age on the prevalence 
of co-morbidities among the different groups.
PRS20
the imPact of Smoking on hoSPital coStS in timeS of cRiSiS; an 
additional BuRden to the vulneRaBle gReek health caRe SyStem
Tsalapati K., Athanasakis K., Pavi E., Kyriopoulos J.
National School of Public Health, Athens, Greece
objeCtives: Smoking has a tremendous impact on public health and has been a 
cause of major concern in Greece for more than twenty years. In times of economic 
recession when household income drops and health spending is decreasing, the 
demand for health services is transferred to the public sector. In light of the above, 
the aim of this study was to measure the number of smoking-related hospitaliza-
tions and the additional hospital costs for the treatment of smoking-attributable 
diseases. Methods: A prevalence-based disease specific approach was used for the 
calculations. Greek-specific smoking-attributable fractions (SAFs) were calculated 
for all smoking-related diseases, coded according to the International Classification 
of Diseases ICD-10. Smoking attributable morbidity was obtained by applying the 
SAFs to all public hospital admissions for 2011. Total hospital costs associated with 
smoking were calculated by applying the smoking-attributable admissions to each 
DRG rate. Results: For Greece, lung cancer (C33-C34), bronchitis and emphysema 
(J40-J42, J43) presented the highest disease-specific SAF with a value of 88.4% and 
88.1% respectively. In 2011, smoking was responsible for 199,028 hospital admis-
sions (8.9 % of total). Smoking-attributable hospital costs, based on the current 
pricing DRG system, has reached 400,011,801€ representing 7.7% of public hospital 
budgets. Ischemic heart disease (I20-I25) was found to be the main cost driver (90.3 
million € ), followed by other circulatory diseases (I00-I09, I26-I51) (55.8 million€ ) and 
pneumonia, influenza (J10-J18) (52.6 million € ). ConClusions: Despite evidence 
of a decreasing trend, smoking is still a considerable public health issue in Greece 
and has a great impact on public health care system. Vigorous efforts have been 
implemented to promote a smoke-free environment and to enforce existing anti-
smoking legislation however the Greek society still experiences a high proportion 
of smoking-attributable admissions and hospital treatment costs. The findings of 
this study further corroborate a call for stronger support of cost-effective tobacco 
control policies.
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PulmonaRy diSeaSe aS comPaRed to otheR chRonic diSeaSeS
Mapel D., Roberts M., Von Worley A.
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objeCtives: Surveys have found high rates of pain medication use among COPD 
patients. However, few data exist on how chronic pain affects health care utilization. 
We examined how chronic pain affects direct medical costs in COPD and a matched 
cohort of patients with other chronic diseases. Methods: We conducted a retro-
spective analysis using claims data from one managed care system. COPD patients 
were matched by age, sex, insurance type, and encounter type to persons with 
other chronic conditions but without COPD [Alzheimer’s, atrial fibrillation, cancer, 
kidney disease, acute myocardial infarction, diabetes, heart failure, ischemic heart 
disease, rheumatoid/osteoarthritis (RA/OA), and stroke]. Chronic pain was indicated 
by pain-associated diagnoses, procedures for pain interventions, or prescription 
fills for pain medications. Results: The study cohort (7,952 COPD patients, 15,904 
non-COPD) was 58% female; mean age, 69. A higher percentage of COPD patients 
were chronic users of any pain medication (41.2% vs 31.5%, P< 0.0001). The only 
patients’ treatment adherence and persistence. Methods: A systematic review 
of the literature was performed in MedLine/PubMed, Cochrane Library, ISI WOK, 
MEDES, IBECS, CSIC, Google Scholar (2002-2012) to identify articles referred to 
direct COPD cost and treatment persistence and adherence. Based on the direct 
cost data extracted, the annual cost difference between an adherent and non-
adherent and a persistent and non-persistent patient in Spain was estimated. 
Costs were updated to € , 2012. Results: A total of 48 articles were included (9 
Spanish; 39 international). The mean annual direct cost of a COPD patient in Spain 
varies between € 301 and € 4.226, depending on the publication. Patients’ adherence 
and persistence on COPD treatment and their annual costs was analyzed in 3 arti-
cles (no Spanish publications identified). Multiple inhaled treatments and devices 
of complex use contribute to poor adherence and persistence and to higher medi-
cal resources use and more exacerbations. Treatment adherence and persistence 
implies a 9% and 3% decrease in mean annual direct cost of a COPD patient, respec-
tively, while non-adherence and non-persistence means an increase of 5% and 
13%. The difference between the mean annual direct cost associated to adherent 
and to non-adherent patient varies from € 43 to € 601 (depending on the selected 
publication) and rises up to € 89 to € 1.674 in severe COPD patients. A difference 
between annual direct cost in persistent and non-persistent patient was estimated 
in € 47 to € 666 that reached € 99 to € 1.855 in severe COPD patients. ConClusions: 
Treatment adherence and persistence information is scarce. Therapeutic strategies 
improving patient adherence and persistence may optimize outcomes contribute 
to COPD costs contain.
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objeCtives: The Casemix databases contain clinical costing information from hos-
pitals in Malaysia, Indonesia and the Philippines. The objective of this study was to 
determine burden of pneumonia in these three countries. Methods: Pneumonia 
cases occurring in a single year were identified using ICD10 codes, J10-J18. Patients 
were further categorized into community-acquired pneumonia (CAP) or hospital-
acquired pneumonia (HAP); CAP if they had 1) a primary diagnosis of pneumonia, 
or 2) secondary diagnosis of pneumonia with primary diagnosis of a respiratory 
condition; HAP cases had pneumonia in any of the secondary diagnosis fields with 
non-respiratory primary diagnoses. Descriptive analysis was performed to ascertain 
patient age groups, mean age, mean length of stay (LOS) and case fatality rates 
(CFR). Results: A total of 15,851 pneumonia cases in year 2010 for Indonesia and 
Philippines and 2011, for Malaysia were included in the analysis. The mean age 
of patients was 47.5 years in Malaysia, 36.6 years in Indonesia and 23.5 years in 
Philippines. There was a preponderance of CAP cases among the very young and 
the very old while HAP cases were more likely to occur in older persons. The overall 
CFR of all pneumonia hospitalizations was 11.5% for Malaysia, 5.2% for Indonesia 
and 3.6% for Philippines. The cost of hospitalization was USD 1,177.50, USD 1,103.80 
and USD 254.30 in Malaysia, Indonesia and Philippines respectively. The mean LOS 
in days was 9.2, 8.0 and 6.6 in the three countries, respectively. ConClusions: 
Our study is the first to utilize these databases to study and compare the burden of 
pneumonia across three countries in Asia. The CFR and LOS varied in each of the 
countries likely due to a variety of reasons including differences in socio-economic 
conditions, patterns of infection as well as health system differences. In conclu-
sion, pneumonia is significant burden in the South East Asian countries studied.
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objeCtives: To evaluate cost and cost-effectiveness of tiotropium monotherapy 
administered for 24 months (18 mcg die) in patients suffering from mild-to-
moderate and severe chronic obstructive pulmonary disease (COPD). Methods: 
A recent published study showed that tiotropium monotherapy enables a sig-
nificant minimization of morbidity in two groups of patients corresponding to 
predicted FEV1 baseline values ≤ 50% (A) and > 50% (B). Clinical outcomes (days 
in hospital, visits in general ward, cycles of systemic steroids, cycles of antibiotics 
and maintenance therapy drugs) were evaluated from the Italian NHS perspective. 
In order to perform cost-effectiveness analysis, FEV1 value, available for each 
patient, was converted in SGRQ score using a published multivariate linear model; 
then utilities were obtained through the Ståhl equation. Results: Results from 
comparison between 24 months of standard therapy and subsequent 24 months 
of tiotropium monotherapy show that hospitalization cost, which represents the 
driving treatment cost, drops from 74.1% to 67.3% (A) and from 64.5% to 31.6% 
(B) of the total cost; differently maintenance therapy cost increases but it is 
more than offset by the savings accruing from the shortening of hospitalization. 
Furthermore, cost-effectiveness results reveal a mean saving of 216 € (A) and 
900 € (B) other than a mean gain of 0.07 QALY(A) and 0.03 QALY(B). Dominance 
of tiotropium calculated only with patients completing treatment course reveal 
that in almost 30% (A) and 37% (B) of subjects tiotropium strategy is dominant 
while only in 2% (A) and 7% (B) of cases are associated to costs increment and 
worsening on quality of life. ConClusions: These results suggest that adop-
tion of tiotropium as unique treatment in selected mild-to-moderate and severe 
